GLMD Stock Shot Up 55% Today After Rising 27% In 5 Days – What’s The Latest On Its Parkinson’s Disease Therapy?

• The new Aramchol formulation uses lipid nanoparticles delivered via injection and is designed to cross the blood–brain barrier.
• Initial data showed that Aramchol reduced harmful protein buildup without causing toxicity.
• The formulation was developed in collaboration with Barcode Nanotech.

Shares of Galmed Pharmaceuticals (GLMD) soared more than 55% on Thursday, after the biotech firm launched a new brain-penetrating formulation of its flagship drug Aramchol.

GLMD stock climbed above $1 for the first time since December 19. Thursday’s rally comes after a 27% gain over the last five sessions.

The upmove comes at a crucial time as Galmed has struggled to remain compliant with Nasdaq’s listing rules. On Jan. 30, 2026, the company received a notice from Nasdaq for failing to meet the $1 minimum bid price requirement. Galmed was given 180 days to regain compliance, with the deadline on July 28, 2026.

Early Data Shows Promise In Preventing Disease Progression

The new Aramchol formulation uses lipid nanoparticles delivered via injection and is designed to cross the blood–brain barrier (BBB), a major obstacle that prevents most drugs from reaching the brain. This can be especially useful to treat central nervous system disorders like Parkinson’s disease.

Initial data showed that Aramchol reduced harmful protein buildup (α-synuclein) without causing toxicity. This suggests it could help slow or prevent disease progression. The formulation was developed in collaboration with Barcode Nanotech.

“Subject to the regulatory advice we are now seeking, we are planning to advance Aramchol to a PoC Ph1b/2 studies in PD patients in H2 2026,” said Allen Baharaff, Galmed's Co-founder and CEO.

How Did Retail Traders React?

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘extremely high’ message volumes.

One user said the stock was consolidating ahead of the next rally. GLMD shares had gained more than 70% after the opening bell.

Year-to-date, the stock has gained more than 12%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.